Arvinas (ARVN) Preferred Stock Liabilities (2017 - 2018)
Arvinas' (ARVN) quarterly Preferred Stock Liabilities came in at $315.2 million in Q3 2018, up 657.43% year-on-year from $41.6 million in Q3 2017, and up 655.57% quarter-over-quarter from $41.7 million in Q4 2017.
Arvinas (ARVN) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Arvinas' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $315.2 million for Q3 2018.
- On a quarterly basis, Preferred Stock Liabilities rose 657.43% year-over-year to $315.2 million in Q3 2018; TTM through Sep 2018 was $315.2 million, a 657.43% increase from a year earlier, with the FY2017 full-year figure at $41.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $315.2 million in Q3 2018 per ARVN's latest filing, from $41.7 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $315.2 million in Q3 2018 and bottomed at $41.6 million in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 315.17 Mn |
| Dec 31, 2017 | 41.71 Mn |
| Sep 30, 2017 | 41.61 Mn |